{"nctId":"NCT01994109","briefTitle":"Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects","startDateStruct":{"date":"2013-11"},"conditions":["Sialorrhea"],"count":187,"armGroups":[{"label":"MYOBLOC 2500 U","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: MYOBLOC"]},{"label":"MYOBLOC 3500 U","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: MYOBLOC"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: PLACEBO"]}],"interventions":[{"name":"MYOBLOC","otherNames":["rimabotulinumtoxinB, botulinum toxin type B"]},{"name":"PLACEBO","otherNames":["volume-matched placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Seeking treatment for troublesome sialorrhea for at least 3 months that is occurring secondary to any disorder or related to any cause\n* Investigator sites will review entire list of inclusion criteria with potential subjects\n\nExclusion Criteria:\n\n* Any known prior exposure to botulinum toxin type B, or known adverse reaction or sensitivity to botulinum toxin type A, or known sensitivity to any of the MYOBLOC solution components.\n* Prior botulinum toxin treatment to the salivary glands at any time\n* Investigator sites will review entire list of exclusion criteria with potential subjects","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)","description":"Change weight of expectorated saliva at a Week 4 post-injection visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.03"},{"groupId":"OG001","value":"-0.36","spread":"0.03"},{"groupId":"OG002","value":"-0.07","spread":"0.03"}]}]}]},{"type":"PRIMARY","title":"Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A)","description":"CGI-C was assessed on a 7-point scale ranging from \"very much improved\" to \"very much worse\" with 1 assigned to \"very much improved\" and 7 assigned to \"very much worse\"; ranging from a minimum score of 1 and a maximum score of 7.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":"0.12"},{"groupId":"OG001","value":"2.45","spread":"0.12"},{"groupId":"OG002","value":"3.59","spread":"0.13"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":63},"commonTop":["Dry mouth","Dental caries","Fall","Dysphagia","Dizziness"]}}}